Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis

뉴스 본문을 불러오고 있어요.

Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis | 웨이프 WAPE

Reported June 29, 2026: Abivax Reports Phase 3 Maintenance Data As Obefazimod Shows Durable Remission And Favorable Safety In Refractory Ulcerative Colitis

기사 요약

관련 종목

댓글 —